NAFLD is the hepatic manifestation of multiple organ cross-talk due to shared mechanisms, including insulin resistance and chronic inflammation factors such as tumor necrosis factor-alpha and interleukin-6, which contribute to increased CVD events and risk of cardiovascular mortality [12,24,25]. This evidence concerns the gene IL6 and metabolic dysfunction-associated steatotic liver disease.